Most recently reported pay: £6.1M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Oct 21, 2026https://www.businesswire.com/news/home/20261020102530/en/Ionis-partner-GSK-announces-Hibsago-bepirovirsen-approved-in-the-U.S.-for-the-treatment-of-chronic-hepatitis-B-CHB/sentiment +0.90
GSK lung cancer drug shows 61% response rate in early global trial
Oct 19, 2026https://www.proactiveinvestors.com/companies/news/1100280sentiment +0.60
GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
Oct 13, 2026https://www.proactiveinvestors.com/companies/news/1100016sentiment +0.10
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Oct 12, 2026https://www.etftrends.com/leveraged-inverse-content-hub/biotechs-rebound-reality-surging-ma-deals-meet-retail-skepticism/sentiment +0.50
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
Oct 8, 2026https://www.prnewswire.com/news-releases/viola-davis-partners-with-gsk-to-educate-adults-50-and-older-about-their-shingles-risk-302902400.htmlsentiment +0.40
Addex Therapeutics Announces Executive Management Changes
Oct 2, 2026https://www.globenewswire.com/news-release/2026/10/02/3373503/0/en/addex-therapeutics-announces-executive-management-changes.htmlsentiment +0.00
